Search Results - "Kraft, Katlyn"

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors by Bagegni, Nusayba A., Park, Haeseong, Kraft, Katlyn, O-Toole, Maura, Gao, Feng, Waqar, Saiama N., Ratner, Lee, Morgensztern, Daniel, Devarakonda, Siddhartha, Amin, Manik, Baggstrom, Maria Q., Liang, Chris, Selvaggi, Giovanni, Wang-Gillam, Andrea

“…Purpose Vorolanib is a multi-target tyrosine kinase inhibitor with anti-angiogenic properties. This study aimed to evaluate the tolerability, safety and…”
Get full text

Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer by Park, Haeseong, Iglesia, Michael, Pedersen, Katrina Sophia, Grierson, Patrick, Hu, Zishuo Ian, Suresh, Rama, Tan, Benjamin R., Trikalinos, Nikolaos, Aranha, Olivia, Navo, Katherine, DeNardo, David G., Ciorba, Matthew A., Kraft, Katlyn, Gao, Feng, Martinez, Elizabeth, von Roemeling, Reinhard, Geissler, Felix, Lim, Kian-Huat

“…TPS4168 Background: Activated NFκB has been linked to aggressive phenotype, poor survival outcomes and resistance to chemotherapy in multiple gastrointestinal…”
Get full text

A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors by Bagegni, Nusayba Ali, Tan, Benjamin R., Park, Haeseong, Kraft, Katlyn, Amin, Manik A., Lim, Kian-Huat, Morgensztern, Daniel, Pedersen, Katrina, Suresh, Rama, Trikalinos, Nikolaos, Wang-Gillam, Andrea

“…Abstract only TPS472 Background: Immune CPIs have become a standard treatment option for many advanced malignancies, including gastric (G)/GE junction (GEJ)…”
Get full text